Purchase Order HHSN269201700730P

<p>The NIH Clinical Center awarded a purchase order to Biomerieux Inc. on May 29, 2018, with a ceiling value of $9,544.74. The order carries firm fixed-price terms and no set-aside designation. Place of performance is Bethesda, Maryland. The ultimate completion date is June 8, 2018.</p>

<p>The NIH Clinical Center awarded a purchase order to Biomerieux Inc. on April 16, 2018, for $9,166.20 with a firm fixed price structure and no set-aside designation. Place of performance is Bethesda, Maryland. The order ceiling is due for ultimate completion on April 17, 2018. The source does not specify the detailed scope of supplies or services being procured under this purchase order.</p>

<p>The NIH Clinical Center awarded a purchase order to Biomerieux Inc. for $14,703.00 on April 16, 2019, with completion targeted for April 15, 2020. Work is performed in Bethesda, Maryland. The order is firm fixed price with no set-aside designation. The specific requirements are not detailed in the source material.</p>

<p>The NIH Clinical Center awarded a purchase order to Biomerieux Inc. for $17,310.26 on December 1, 2017, with a ceiling value of $17,310.26 under firm fixed-price terms. The order is for diagnostic equipment, reagents, and test kits to support microbiological testing and clinical laboratory operations. Performance occurs at Bethesda, Maryland. The order is scheduled for completion by December 8, 2017.</p>

<p>The NIH Clinical Center awarded a purchase order to Biomerieux Inc. on March 30, 2018, for $14,285.84 with a firm fixed-price structure and an ultimate completion date of April 29, 2018. Place of performance is Bethesda, Maryland. The order procures in vitro diagnostic equipment, reagents, or test kits—Biomerieux's core offerings in microorganism identification and clinical laboratory testing. No set-aside was applied to this acquisition.</p>

The NIH Clinical Center issued a purchase order to Biomerieux Inc. on July 20, 2018, with a ceiling value of $263,153.78 for firm fixed-price diagnostic supplies and equipment. The order was administratively de-obligated on a de-obligation notice dated July 20, 2018, to close unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026 close of the period of availability. Place of performance is Bethesda, Maryland. The...

Biomerieux Inc. was awarded a purchase order valued at $24,995.61 by the NIH Clinical Center on July 9, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price contract represents a direct procurement with no set-aside designation. The NIH Clinical Center, a component of the National Institutes of Health, procures specialized diagnostic and laboratory solutions to support its clinical research and patient care missions. Biomerieux, operating under the trade name Vitek...

<p>The National Institutes of Health Clinical Center issued a purchase order to Biomerieux Inc. on July 6, 2026, with a ceiling value of $68,941.80 for diagnostic equipment and supplies. Place of performance is Emigration Canyon, Utah. The order is firm fixed price with an ultimate completion date of June 28, 2027. No set-aside category applies.</p>

The National Institutes of Health Clinical Center awarded a $24,900 purchase order to Biomerieux Inc. to provide unspecified products or services. Performance will take place in Emigration Canyon, Utah over a two-week period concluding on September 30, 2023. The prime contractor is Biomerieux Inc.'s Biomerieux, Inc. Division. Funding is provided by the Department of Health and Human Services for the NIH Clinical Center's use. No additional details were provided regarding the original...

This is a $75,025.40 firm-fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Biomerieux Inc., a global leader in in vitro diagnostics and laboratory testing solutions. The contract is for the supply of reagents and supplies required for molecular patient care testing, with a period of performance ending on February 8, 2022. The contract does not have a set-aside designation. Biomerieux Inc. is the prime contractor, and there is no information...